Dr. Meinhardt on the Impact of the RESORCE Study in HCC

Gerold Meinhardt, MD
Published: Tuesday, May 09, 2017



Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma (HCC).

Regorafenib (Stivarga), was recently approved by the FDA for use in patients with HCC that have progressed on Sorafenib (Nexavar). This approval was based on the findings of the phase III RESORCE trial, which showed a significant improvement in survival with a manageable safety profile.

Meinhardt says that this trial provides hope for new therapies in a disease that is historically difficult to treat.
 


Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma (HCC).

Regorafenib (Stivarga), was recently approved by the FDA for use in patients with HCC that have progressed on Sorafenib (Nexavar). This approval was based on the findings of the phase III RESORCE trial, which showed a significant improvement in survival with a manageable safety profile.

Meinhardt says that this trial provides hope for new therapies in a disease that is historically difficult to treat.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x